

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder [ID5105]

## Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Alexion (ravulizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Brain and Spine Foundation</li> <li>• Brain Charity</li> <li>• Carers UK</li> <li>• Contact</li> <li>• Eyecare Trust</li> <li>• Fight for Sight</li> <li>• Macular Society</li> <li>• Myaware</li> <li>• National Federation of the Blind UK</li> <li>• Neurological Alliance</li> <li>• OBAC</li> <li>• Royal National Institute of Blind People</li> <li>• SeeAbility</li> <li>• Sense</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Thomas Pocklington Trust</li> <li>• Transverse Myelitis Society</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Optometrists</li> <li>• British and Irish Orthoptic Society</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Ophthalmic Anaesthesia Society</li> <li>• College of Optometrists</li> <li>• Institute of Neurology</li> <li>• National Neuroscience Advisory</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• Neurological Alliance of Scotland</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Council for the Blind</li> <li>• Wales Neurological Alliance</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Research UK</li> <li>• Cochrane Eyes and Vision Group</li> <li>• Cochrane UK</li> <li>• Eye Hope</li> <li>• Genomics England</li> <li>• Institute of Ophthalmology, University College London</li> </ul>

Final stakeholder list for the evaluation of ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder [ID5105]

Issue date: March 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<p>Group</p> <ul style="list-style-type: none"> <li>• Optical Confederation</li> <li>• Primary Care and Community Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Ophthalmologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NMOSD Service, John Radcliffe Hospital, OUH NHS Foundation Trust</li> <li>• NMOSD Service, The Walton Centre NHS Foundation Trust</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• National Eye Research Centre</li> <li>• National Hospital for Neurology and Neurosurgery</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.